201 related articles for article (PubMed ID: 36923928)
1. AIM2 promotes renal cell carcinoma progression and sunitinib resistance through FOXO3a-ACSL4 axis-regulated ferroptosis.
Wang Q; Gao S; Shou Y; Jia Y; Wei Z; Liu Y; Shi J; Miao D; Miao Q; Zhao C; Liu C; Yang H; Xu T; Zhang X
Int J Biol Sci; 2023; 19(4):1266-1283. PubMed ID: 36923928
[TBL] [Abstract][Full Text] [Related]
2. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
[TBL] [Abstract][Full Text] [Related]
3. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma.
Liu Y; Cheng G; Huang Z; Bao L; Liu J; Wang C; Xiong Z; Zhou L; Xu T; Liu D; Yang H; Chen K; Zhang X
Cell Death Dis; 2020 Jul; 11(7):515. PubMed ID: 32641718
[TBL] [Abstract][Full Text] [Related]
4. circPTPN12 promotes the progression and sunitinib resistance of renal cancer via hnRNPM/IL-6/STAT3 pathway.
Shou Y; Yue C; Wang Q; Liu J; Xu J; Miao Q; Liu D; Yang H; Liu Y; Zhang X
Cell Death Dis; 2023 Mar; 14(3):232. PubMed ID: 37002206
[TBL] [Abstract][Full Text] [Related]
5. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
6. miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma.
Sekino Y; Sakamoto N; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
Oncology; 2019; 97(3):164-172. PubMed ID: 31195398
[TBL] [Abstract][Full Text] [Related]
7. Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress.
Xiong Z; Yuan C; Shi J; Xiong W; Huang Y; Xiao W; Yang H; Chen K; Zhang X
Theranostics; 2020; 10(25):11444-11461. PubMed ID: 33052225
[No Abstract] [Full Text] [Related]
8. Circular RNA circSNX6 promotes sunitinib resistance in renal cell carcinoma through the miR-1184/GPCPD1/ lysophosphatidic acid axis.
Huang KB; Pan YH; Shu GN; Yao HH; Liu X; Zhou M; Wei JH; Chen ZH; Lu J; Feng ZH; Chen W; Han H; Zheng ZS; Luo JH; Zhang JX
Cancer Lett; 2021 Dec; 523():121-134. PubMed ID: 34626691
[TBL] [Abstract][Full Text] [Related]
9. Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis.
Wu Z; Peng Y; Xiong L; Wang J; Li Z; Ning K; Deng M; Wang N; Wei W; Li Z; Dong P; Yu C; Zhou F; Zhang Z
Cancer Med; 2022 Oct; 11(19):3674-3686. PubMed ID: 35476809
[TBL] [Abstract][Full Text] [Related]
10. Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression.
Shi H; Sun Y; He M; Yang X; Hamada M; Fukunaga T; Zhang X; Chang C
Oncogene; 2020 Jan; 39(3):530-545. PubMed ID: 31501521
[TBL] [Abstract][Full Text] [Related]
11. Splice variants of lysosome‑associated membrane proteins 2A and 2B are involved in sunitinib resistance in human renal cell carcinoma cells.
Nishikawa R; Osaki M; Sasaki R; Ishikawa M; Yumioka T; Yamaguchi N; Iwamoto H; Honda M; Kabuta T; Takenaka A; Okada F
Oncol Rep; 2020 Nov; 44(5):1810-1820. PubMed ID: 32901843
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma.
Zhao T; Bao Y; Gan X; Wang J; Chen Q; Dai Z; Liu B; Wang A; Sun S; Yang F; Wang L
Theranostics; 2019; 9(21):6175-6190. PubMed ID: 31534544
[No Abstract] [Full Text] [Related]
13. Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma.
Adelaiye-Ogala R; Damayanti NP; Orillion AR; Arisa S; Chintala S; Titus MA; Kao C; Pili R
Cancer Res; 2018 Jun; 78(11):2886-2896. PubMed ID: 29572225
[TBL] [Abstract][Full Text] [Related]
14. CircRNA_001895 promotes sunitinib resistance of renal cell carcinoma through regulation of apoptosis and DNA damage repair.
Tan L; Huang Z; Chen Z; Chen S; Ye Y; Chen T; Chen Z
J Chemother; 2023 Feb; 35(1):11-18. PubMed ID: 34927575
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.
Jin J; Xie Y; Zhang JS; Wang JQ; Dai SJ; He WF; Li SY; Ashby CR; Chen ZS; He Q
Drug Resist Updat; 2023 Mar; 67():100929. PubMed ID: 36739809
[TBL] [Abstract][Full Text] [Related]
16. Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation.
Marona P; Górka J; Kwapisz O; Jura J; Rys J; Hoffman RM; Miekus K
Cell Death Dis; 2022 Sep; 13(9):814. PubMed ID: 36138026
[TBL] [Abstract][Full Text] [Related]
17. G-Protein-coupled Estrogen Receptor 1 Agonist G-1 Perturbs Sunitinib Resistance-related Phosphoproteomic Signatures in Renal Cell Carcinoma.
Chen SK; Wang YC; Lin TY; Wu HJ; Huang CJ; Ku WC
Cancer Genomics Proteomics; 2021; 18(3):207-220. PubMed ID: 33893075
[TBL] [Abstract][Full Text] [Related]
18. Genetic variants in a long noncoding RNA related to Sunitinib Resistance predict risk and survival of patients with renal cell carcinoma.
Xing Q; Li R; Xu A; Qin Z; Tang J; Zhang L; Tang M; Han P; Wang W; Qin C; Du M; Zhang W
Cancer Med; 2019 Jun; 8(6):2886-2896. PubMed ID: 31038847
[TBL] [Abstract][Full Text] [Related]
19. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant.
Tsuruda M; Yoshino H; Okamura S; Kuroshima K; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
PLoS One; 2020; 15(5):e0232545. PubMed ID: 32379831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
